U.S. FDA· @FDA · X·· 3 小时前精选AI 评分60
AI 导读
FDA 批准 Tecelera 的疗效补充申请，将其适应症扩展至 12 岁及以上、既往接受过化疗的不可切除或转移性滑膜肉瘤儿科患者。FDA 表示这是其在生物制品领域对抗儿童癌症的最新进展，相关消息发布于儿童癌症宣传月期间。
推荐理由
FDA 官方披露 Tecelera 疗效补充申请获批，读者可了解其儿童滑膜肉瘤适应症的具体人群与既往治疗限定。
正文
FDA has been making strides in biologics when it comes to combating childhood cancer. The most recent approval of an efficacy supplement for Tecelera, expanding its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy. #ChildhoodCancerMonth https://www.fda.gov/vaccines-blood-biologics/news-events-biologics/whats-new-biologics
来源：U.S. FDA · x.com